期刊文献+

糖尿病模型大鼠强骨宝方含药血清对成骨细胞培养上清液IL-6、TNF-α及AGEs的影响 被引量:8

Influences of QiangGuBao pharmaco-serum on IL-6,TNF-α and AGEs of osteoblast cultured supernate in diabetic rat-model
下载PDF
导出
摘要 目的:探讨强骨宝方糖尿病模型大鼠含药血清对体外培养成骨细胞上清液中IL-6、TNF-α及AGEs的影响。方法:采用胰蛋白酶-Ⅱ型胶原酶消化法从1-2日龄SD大鼠颅盖骨中分离出成骨细胞,鉴定细胞后,分别用20%不灭活的强骨宝方糖尿病模型大鼠含药血清、单纯的糖尿病模型大鼠血清及正常大鼠血清加入成骨细胞培养体系,培养5d、7d及10d,分时段检测培养上清液中IL-6、TNF-α及AGEs的量。结果:强骨宝含药血清组第5d上清液中的IL-6(78.38±18.35)pg/ml、TNF-α(0.5731±0.4316)ng/ml及AGEs(71.52±22.13)荧光值/每毫克蛋白均显著低于模型对照组(P<0.01),并接近于空白对照组;而模型对照组各时段3项指标均显著高于相应的空白对照组(P<0.01),并且3项指标均随培养时间延长而显著升高(P<0.05或P<0.01)。结论:糖尿病模型大鼠血清会促进体外培养的成骨细胞分泌IL-6、TNF-α及AGEs的形成,糖尿病模型大鼠强骨宝方含药血清能有效抑制IL-6、TNF-α在正常水平并控制非酶促糖基化反应及AGEs的产生。 To investigate the influence of pharmaco-serum from diabetic rat-model fed with QiangGuBao on the contents of IL-6,TNF-α and AGEs in the supernate of osteoblas(OB) culture in vitro.Method: OB was isolated from the skull of 1-2 day newly born SD rats by means of Trypsin-collagenase digestion.After the OB was identified,20% pharmaco-serum from diabetic rat-model fed with QiangGuBao and pure serum from diabetic rat-model and serum from normal rat were added to the OB and incubated respectively.After OB was cultured 5d,7d and 10d,the contents of IL-6,TNF-α and AGEs in the supernate of osteoblast were detected.Result: The outcomes of IL-6(78.38±18.35) pg/ml、TNF-α(0.5731±0.4316) ng/ml and AGEs(71.52±22.13) fluorescence value/per milligram protein in different stages in the group of pharmaco-serum were highly significant lower than that of no pharmaco-serum model group(P〈0.01) and the outcomes were close to that of blank group.The outcomes of IL-6,TNF-α and AGEs in different stages in the group of no pharmaco-serum model were highly significant higher than that of blank group(P〈0.01) and the outcomes of three indexes raised significantly with the culture time prolonging(P〈0.05 or P〈0.01).Conclusion: Pure serum from diabetic rat-model can promote secretion of IL-6 and TNF-α and formation of AGEs in OB culture in vitro.Pharmaco-serum from diabetic rat-model fed with QiangGuBao can effectively restrain secretion of IL-6 and TNF-α and control nonenzymic glycation reaction and formation of AGEs.
出处 《中华中医药杂志》 CAS CSCD 北大核心 2007年第10期672-676,共5页 China Journal of Traditional Chinese Medicine and Pharmacy
基金 福建省科技厅青年创新基金项目资助(No.2001J62)
关键词 强骨宝 成骨细胞 白细胞介素-6 肿瘤坏死因子-α 高级糖基化终末产物 糖尿病模型大鼠含药血清 实验研究 QiangGuBao Osteoblast IL-6 TNF-α AGEs Pharmaco-serum from diabetic rat-model Experimental study
  • 相关文献

参考文献10

二级参考文献107

  • 1张金梁,崔志清.中药血清药理学实验方法的研究探微[J].中医药学刊,2004,22(12):2271-2272. 被引量:14
  • 2王筠,张军平.中药血清药理学实验方法研究概况[J].天津中医药,2005,22(1):86-88. 被引量:29
  • 3[德]HG沃格尔 [美]W H沃格尔编著 杜冠华 李学军 张永祥等译.药理学实验指南-新药发现和药理学评价[M].北京:科学出版社,2001.699.
  • 4[1]Vlassara H.Recent progress in advanced glycation end products and diabetic complications.Diabetes,1997,46(Suppl 2):s19-25.
  • 5[2]Chellan P,Nagaraj RH.Protein crosslinking by the maillard reaction:dicarbonyl-derived imidazolium crosslinks in aging and diabetes.Arch Biochem Biophys.1999,368:98-104.
  • 6[3]Bucala R,Makita Z,Vega G,et al.Modification of LDL by advanced glycosylation end products contributes to the dyslipidemia of diabetes and renal inufficiency.Proc Natl Acad Sci USA,1994,91:9441-9445.
  • 7[4]Chiarelli F,de Martino M,Mezzetti A,et al.Advanced glycation end products in children and adolescents with diabetes:relation to glycemic control and early microvascular complications.J Pediar.1999,134:486-491.
  • 8[5]Makita Z,Bucala R,Rayfield EJ,et al.Reactive glycosylation end products in diabetic uraemia and treatment of renal failure.Lancet,1994,343:1519-1522.
  • 9[6]Brett J,Schmidt AM,Yan SD,et al.Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissue.Am J Pathol.1993,143:1699-1712.
  • 10[7]Libby P,Hason GK.Involvement of the immune system in human atherogenesis:current knowledge and unanswered questions.J Lab Invest,1991,64:5-15.

共引文献116

同被引文献87

引证文献8

二级引证文献67

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部